Melchior S W, Brown L G, Figg W D, Quinn J E, Santucci R A, Brunner J, Thüroff J W, Lange P H, Vessella R L
Department of Urology, Johannes Gutenberg-University Medical School, 55131 Mainz, Germany.
Int J Oncol. 1999 Mar;14(3):501-8. doi: 10.3892/ijo.14.3.501.
Phenylbutyrate (PB) is a potent differentiating agent and currently under investigation for the treatment of prostate cancer (CaP) and other malignancies. We have studied the impact of PB in vitro and in vivo on differentiation, proliferation and apoptosis in the LNCaP and LuCaP 23.1 prostate cancer xenograft models. In vitro we found that i) PB increased PSA secretion/cell, ii) inhibited cell proliferation in a time- and dose-dependent manner resulting in a cell cycle arrest in G1-phase and iii) induced apoptosis at concentrations of 2.5 mM after 3 days of treatment. In PB treated animals tumor growth stabilized or regressed. Combination of castration and PB treatment had a synergistic antiproliferative effect. The growth-inhibitory and differentiating properties and a low toxicity profile of PB provide rationale for further clinical studies in patients with CaP.
